Gene expression profiling of cancer cells with genetic disruption of DNA methyltransferases [Agilent-026652]
Ontology highlight
ABSTRACT: Maximizing DNA methyltransferase (DNMT’s) inhibition for cancer therapy requires defining the roles and interactions between these enzymes for maintaining the widespread DNA methylation abnormalities in cancer. Combining genetic and shRNA depletion in colon and other cancer cells reveals that DNMT1 is extremely dominant in this maintenance, with DNMT’s 3A and 3B playing minor roles, at all genomic loci including promoters and enhancers. Reducing DNMT1 below a deep threshold level, especially at promoters, is required for reversing abnormal DNA methylation and re-expressing key tumor suppressor genes. Current DNMT inhibitors (DNMTis) are challenged, at tolerable patient doses, for achieving such reductions. We introduce a new approach in which reducing levels of the DNMT targeting protein, UHRF1, complements low DNMTi doses to DNA demethylate and reactivate expression of such genes.
ORGANISM(S): Homo sapiens
PROVIDER: GSE93135 | GEO | 2017/01/13
SECONDARY ACCESSION(S): PRJNA360119
REPOSITORIES: GEO
ACCESS DATA